Written agreement from FDA for single-arm, open-label, baseline-controlled registrational trial evaluating composite primary endpoint of improvement in CGI-I and gain of developmental milestone/skill ...
Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy NGN-401 for Rhett syndrome. Neurogene (NGNE) said that a patient who had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback